Educational webinar features a panel of leading transplant clinicians discussing improving patient outcomes in the era of COVID-19.

MANSFIELD, MA — Transplant Genomics (“TGI”), the leading personalized diagnostics company committed to improving organ transplant outcomes worldwide, and Viracor, one of the largest and most recognized infectious diseases testing laboratories in the United States, are excited to join the American Society of Nephrology (ASN) for Kidney Week, the society’s annual meeting and scientific conference, October 22-25. For 2020, Kidney Week has transitioned to a digital meeting. Participating together under the joint brand of Eurofins Transplant Diagnostics, scientific and clinical experts from both companies will be available for discussions in the digital exhibit hall throughout the meeting.

Following Kidney Week, Eurofins Transplant Diagnostics will host a complimentary educational webinar, “Post-Transplant Patient Management for Rejection, Infection and Emerging Pathogens,” on Monday, October 26, at 2:00 pm ET / 1:00 PM CT. The webinar will feature a panel of world-leading transplant experts who will share insights into the care of organ donors and transplant recipients through rejection testing, infection management and the impact of emerging pathogens including Coronavirus SARS-CoV-2.

The webinar topics will include:
“Safeguarding Donor Organs In A COVID Epicenter” – Dr. Amy Friedman, Executive Vice President & Chief Medical Officer, LiveOnNY
“CoV2 Vaccination and Transplant Patients” – Dr. Michael G. Ison, Director of Divisions of Infectious Disease and Organ Transplantation, Northwestern University Feinberg School of Medicine
“CMV Cell-Mediated Immunity Assays in Clinical Practice” – Dr. Dimitrios Farmakiotis, Assistant Professor of Medicine, Director of Transplant and Oncology Infectious Disease, Warren Alpert Medical School of Brown University
“Overview of TruGraf and TRAC” – Dr. John Holman, Vice President, Medical Affairs, Transplant Genomics

Members of the American Society of Nephrology may register for Kidney Week 2020 at https://www.asn-online.org/education/kidneyweek/.

All nephrologists and other medical professionals can register for the October 26 webinar at http://www.transplantgenomics.com/events.

For more information:
Branden Morris
Transplant Genomics, Inc.
e) brandenmorris@eurofinsus.com
p) 510-745-4707

###

About Transplant Genomics, Inc.
Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. Our flagship product is TruGraf, the only blood test approved by CMS for surveillance and to rule out “silent” subclinical acute rejection in kidney transplant recipients with stable graft function. Test services are offered through TGI’s CLIA laboratory in Fremont, CA. TGI was acquired by Eurofins Scientific in 2019.

Learn more about Transplant Genomics at http://www.trugraf.com.

About Viracor
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific, the global leader in bio-analytical testing, and one of the world leaders in genomic services.

Learn more about Viracor at https://www.viracor-eurofins.com.

About Eurofins Scientific
Eurofins Scientific (hereinafter sometimes “Eurofins” or “the Group”), through its subsidiaries, believes it is a scientific leader in food, environment, pharmaceutical, and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences, and supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group’s objective is to provide its customers with high-quality services, accurate results on time, and expert advice from highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding its technology portfolio and its geographic reach. Through R & D and acquisitions, the Group draws on the latest developments in biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality-oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Learn more about Eurofins at http://www.eurofins.com.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

SOURCE Eurofins Transplant Genomics